Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway

Autor: Wang, M., Han, J., Marcar, L., Black, J., Liu, Q., Li, X., Nagulapalli, K., Sequist, L. V., Mak, R. H., Benes, C. H., Hong, T. S., Gurtner, K., Krause, M., Baumann, M., Kang, J. X., Whetstine, J. R., Willers, H.

Publikováno v: Cancer Research 77(2017), 2018-2028

Lung cancers with activating KRAS mutations are characterized by treatment resistance and poor prognosis. In particular, the basis for their resistance to radiation therapy is poorly understood. Here, we describe a radiation resistance phenotype conf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4577::244a3eef6a0da6d13000c8da720b4297
https://www.hzdr.de/publications/Publ-26980-1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

Autor: Wang M; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Han J; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Jinan Municipal Center for Disease Control and Prevention, Shandong, China., Marcar L; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Black J; University of Colorado School of Medicine, Aurora, Colorado.; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts., Liu Q; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Li X; Laboratory for Lipid Medicine and Technology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts., Nagulapalli K; Center for Computational Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Sequist LV; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Mak RH; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Benes CH; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts., Hong TS; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Gurtner K; Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; OncoRay National Center for Radiation Research in Oncology, Dresden, Germany.; Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Institute of Radiation Oncology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Cancer Consortium (DKTK) Partner Site Dresden and German Cancer Research Center (DKFZ) Heidelberg, Dresden, Germany., Krause M; Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; OncoRay National Center for Radiation Research in Oncology, Dresden, Germany.; Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Institute of Radiation Oncology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Cancer Consortium (DKTK) Partner Site Dresden and German Cancer Research Center (DKFZ) Heidelberg, Dresden, Germany., Baumann M; Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; OncoRay National Center for Radiation Research in Oncology, Dresden, Germany.; Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Institute of Radiation Oncology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Cancer Consortium (DKTK) Partner Site Dresden and German Cancer Research Center (DKFZ) Heidelberg, Dresden, Germany., Kang JX; Laboratory for Lipid Medicine and Technology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts., Whetstine JR; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts., Willers H; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. hwillers@partners.org.

Publikováno v: Cancer research [Cancer Res] 2017 Apr 15; Vol. 77 (8), pp. 2018-2028. Date of Electronic Publication: 2017 Feb 15.